Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental lung cancer drug shows promise but trial halted early

NCT ID NCT06685718

Terminated Disease control Sponsor: BeOne Medicines Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested an experimental drug called BG-60366 in 33 people with advanced EGFR-mutant non-small cell lung cancer. The drug is designed to break down the faulty EGFR protein that drives cancer growth. The study aimed to check safety and find the right dose, but it was terminated before completion, so full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
BG-60366 (a drug that breaks down the faulty EGFR protein in cancer cells)
What this could lead to
If it works, this could point toward a new treatment option for people with EGFR-mutant lung cancer whose disease has stopped responding to current therapies.
What could go wrong
This was a very early (Phase 1) trial that was terminated, so results are limited. The drug may not be safe or effective enough to move forward.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EGFR ACTIVATING MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EGFR ACTIVATING MUTATION EGFR MUTATION-RELATED TUMORS LUNG CANCER NON-SMALL CELL LUNG CANCER NSCLC NSCLC (NON-SMALL CELL LUNG CARCINOMA)

Contacts and locations

Locations

  • Austin Health

    Heidelberg, Victoria, VIC 3084, Australia

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, 100142, China

  • Blacktown Cancer and Haematology Centre

    Blacktown, New South Wales, NSW 2148, Australia

  • Cancer Research South Australia

    Adelaide, South Australia, SA 5000, Australia

  • Chungbuk National University Hospital

    Cheongju-si, Chungcheongbukdo, 28644, South Korea

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215-5418, United States

  • Fondazione Irccs San Gerardo Dei Tintori Sc Oncologia

    Monza, 20900, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli

    Roma, 00168, Italy

  • Guangdong Provincial Peoples Hospital Huifu Branch

    Guangzhou, Guangdong, 510120, China

  • H Puerta de Hierro Majadahonda

    Majadahonda, 28222, Spain

  • Harbour Cancer and Wellness

    Auckland, 1023, New Zealand

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Hospital Universitario Vall Dhebron

    Barcelona, 08035, Spain

  • Liverpool Hospital

    Liverpool, New South Wales, NSW 2170, Australia

  • Memorial Sloan Kettering Cancer Center Mskcc

    New York, New York, 10065-6800, United States

  • Ohio State University

    Columbus, Ohio, 43210-1132, United States

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, VIC 3000, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, QLD 4102, Australia

  • Samsung Medical Center

    GangnamGu, Seoul Teugbyeolsi, 06351, South Korea

  • Seoul National University Hospital

    Seoul, Seoul Teugbyeolsi, 03080, South Korea

  • Severance Hospital Yonsei University Health System

    SeodaemunGu, Seoul Teugbyeolsi, 03722, South Korea

  • Shanxi Bethune Hospital

    Taiyuan, Shanxi, 030032, China

  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicineqiantang Branch

    Hangzhou, Zhejiang, 310018, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, 330006, China

  • The Tumor Hospital Affiliated to Guangxi Medical Universitywuxiang Branch

    Nanning, Guangxi, 530201, China

  • The University of Texas Md Anderson Cancer Center

    Houston, Texas, 77030-4009, United States

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, 300060, China

  • University of Colorado

    Denver, Colorado, 80202-1702, United States

  • Washington University School of Medicine Siteman Cancer Center

    St Louis, Missouri, 63110-1032, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.